Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214629 · ClinicalTrials.gov registry record · Phase 1
A Study for Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01214629 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 54 participants.
The verdict
NCT01214629, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
Interventions
- DRUG pegfilgrastim
- DRUG LY2523355
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214629
The ClinicalTrials.gov registry entry for NCT01214629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pegfilgrastim is the first listed.
NCT01214629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214629 about?
NCT01214629 is a clinical study titled "A Study for Participants With Advanced Cancer". This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
What is the current status of trial NCT01214629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2007-07. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01214629?
The interventions under investigation include: pegfilgrastim (DRUG), LY2523355 (DRUG).
Who is sponsoring clinical trial NCT01214629?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.